Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects

EJNMMI Research

Table 2 Metabolite analysis of ¹⁸F-TFB in plasma and urine of healthy participants

		40 min^a		145 min^a		235 min^a		Accumulative
		Males	Females	Males	Females	Males	Females	Males	Females
Whole blood (SUV)		3.0 ± 0.2	3.1 ± 0.9	2.1 ± 0.2	1.7 ± 0.4	1.7 ± 0.2	1.4 ± 0.4	–	–
Plasma (SUV)		3.8 ± 0.2	3.8 ± 1.0	2.8 ± 0.3	2.1 ± 0.5	2.0 ± 0.1	1.7 ± 0.5	–	–
Urine (%dose)		15 ± 2^b	16 ± 3	13 ± 3	18 ± 3	10 ± 2^b	12 ± 2	40 ± 5^b	46 ± 7
%Intact ¹⁸F-TFB	Plasma	97 ± 2	97 ± 3^c	−^d	−^d	−^d	−^d	–	–
%Intact ¹⁸F-TFB	Urine	96 ± 2	98 ± 1	97 ± 2	98 ± 1	98 ± 1	97 ± 2	–	–

Values are mean ± SD (n = 4)
^aTime points are shown for blood samples; urine samples were collected ~ 10 min later
^bNo urine in third collection of one male subject
^cOne plasma sample was not used because precipitate was observed in the HPLC analysis
^dMetabolite data were not obtained in second and third plasma samples analysis because the low radioactivity levels were below detection limit